The number of COVID-19 cases in India rose to 30,317 on Tuesday evening, while the total death toll so far is 965. Around the world confirmed cases are 3,090,844 and the number of people died is 215,062. Recovered cases from the virus are 918,809.
In a major development, the Health Ministry has said that plasma therapy is still in an experimental stage.
Health Minister Harsh Vardhan said India’s doubling rate of cases has been 8.7 days over the last 14-day period, and cases have doubled at the rate of 10.9 days in the past three days.
Vardhan also noted that India will be able to produce RT-PCR and antibody test kits by May-end. “All processes are at an advanced stage. Production will start after getting approval from ICMR. It will help us in meeting our target of 1 lakh tests per day by May 31. We have issued directions to expedite the development of antibody detection kits, real-time PCR-based detection kits, and vaccines for COVID-19 under ‘Make in India’,” he said.
HRD Minister Ramesh Pokhriyal Nishank had a meeting with State education ministers and instructed them to initiate the evaluation of Board exam answer sheets without waiting for the lockdown to be lifted.
In Mumbai, all police constables aged 55 and above have been sent on compulsory leave. Officials said this policy is being followed because the three police personnel who have died of COVID-19 so far were all over the age of 50, which is regarded as a vulnerable group.
In Surat, Gujarat hundreds of migrant workers protested demanding that they be allowed to return to their native States. This is the third protests in less than a month.
In West Bengal, a crowd which gathered at a market place in Tikiapara, Howrah defying lockdown attacked police personnel. They pelted stones leaving two police injured
News about Vaccine trials
According to WHO, six vaccines had entered human trials as of 23 April, and 77 others were in development. The vast majority of these vaccines use the modern tools of genetic engineering—only four rely on the old-fashioned inactivation technology.
In this pandemic situation, the most important thing is to make a vaccine, no matter what kind of vaccine it is, that’s safe and effective as soon as possible.
An Australian research and clinical facility is preparing to launch human trial of COVID-19 vaccine developed by China. According to Xinhua, Linear Clinical Research, Perth-based clinical research company, has began to recruit healthy adults for the trial within next two months.
S-Trimer vaccine, developed by China-based global biotechnology company Clover Biopharmaceuticals, is among the first COVID-19 vaccines under development. Linear also announced the vaccine trial on their website and called on the interested people to register with the company.
“If you’re healthy and located in Perth, WA, register your interest to participate in our upcoming COVID-19 vaccine study,” the company said.
Protein-based S-Trimer vaccine aims to help the body to produce anti-bodies to fight the virus. “This is one of the most prominent trials globally and involves some of the most renowned vaccine companies,” the agency quoted Jayden Rogers, chief executive of Linear, as saying.